Clinical Trial

Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 3, 2024 (before its estimated April 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-13.
Trial Details
NCT Number NCT06553352
Lead Sponsor The First Affiliated Hospital of Xiamen University
Collaborators: Shanxi Province Cancer Hospital, The First Hospital of Jilin University, Fujian Cancer Hospital, Jiangxi Provincial Cancer Hospital, The Second Affiliated Hospital of Dalian Medical University, Sun Yat-sen University, Huazhong University of Science and Technology
Conditions Follicular Lymphoma, Newly Diagnosed
Enrollment 39 participants
Start Date 2024-03-31
Primary Completion 2026-04-20 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-03